Terms of the deal announced Tuesday are very similar to those the FTC reached with Express Scripts earlier this year, ...

The new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant ...

Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that ...

Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that ...

Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and ...

U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?

GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among ...

The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of ...

The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox ...

Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.

The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer.